Revolutionizing maxillofacial care: Exploring denosumab's impact on giant cell granuloma – A comprehensive case series and literature review

Giant cell lesions (GCLs) of the maxillofacial complex present a therapeutic challenge due to their aggressive nature and potential for recurrence. Traditional treatment modalities often includes surgical intervention with varying degrees of success and associated morbidities. In recent years, denosumab, a monoclonal antibody targeting the RANK ligand pathway, has emerged as a promising alternative in the management of GCLs. This article provides a comprehensive overview of denosumab's efficacy, safety profile, and clinical outcomes in treating GCLs through a meticulous analysis of case series and literature review. We describe denosumab's potential as a novel therapeutic option, offering improved outcomes and reduced morbidity for patients with GCLs in the maxillofacial region with the presentation of two cases using a comprenhesive diagnosis and management. On the other hand, this article highlights the need for further prospective studies to stablish optimal dosing regimens, long-term efficacy, and potential adverse effects, for enhanced patient care and management strategies in this challenging clinical scenario.